 Potent toxicity human monocytes vitro vivo novel approach immunosuppressive therapy Lymphoid cells susceptible excess dAdo inhibitors adenosine deaminase ADA human monocytes sensitive lymphocytes ADA-resistant congener CldAdo Monocytes vitro CldAdo developed DNA strand breaks DNA damage toxicity CldAdo monocytes deoxycytidine inhibitors poly ADP-ribose polymerase partial decrease RNA synthesis gradual decline cellular NAD early biochemical events monocyte DNA damage Low CldAdo concentrations nM monocyte phagocytosis release interleukin CldAdo concentrations dose- time-dependent loss monocyte viability monocytes wk patients cutaneous cell lymphoma rheumatoid arthritis continuous CldAdo infusion marked sensitivity human monocyte function survival CldAdo vitro monocyte depletion patients CldAdo chemotherapy CldAdo dAdo analogues novel therapeutic strategy chronic inflammatory autoimmune diseases inappropriate monocyte deployment function